All Oncology News

Jill Gilbert, MD, discusses how principles of adult learning theory can be applied to hematology/oncology fellowship.

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.

ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.

ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.

Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

A post hoc analysis of the PhALLCON study showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.

Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Cyclosporin/cyclophosphamide after allogeneic stem cell transplant improved outcomes vs cyclosporin/methotrexate in high-risk hematologic malignancies.

TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.

The FDA granted fast track designation to nuvisertib for intermediate- or high-risk myelofibrosis.

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.

Venetoclax and decitabine-cedazuridine demonstrated complete responses and encouraging survival outcomes in newly diagnosed AML.

Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.

Naval Daver, MD, discusses the evolving role of menin inhibition in acute myeloid leukemia and emerging data with revumenib.